Moving towards better predictors of drug-induced torsades de pointes

British Journal of Pharmacology

Volumn 154, Issue 7, 2008, Pages 1550-1553

  Bass, A S ^a   Darpo, B ^b   Valentin, J P ^c   Sager, P ^c   Thomas, K ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Trasthagen   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

Author keywords

Arrhythmia; Cardiac toxicity; Electrocardiogram; hERG; I Kr; Long QT syndrome; QT prolongation; Safety pharmacology; Torsades de pointes; Ventricular repolarization

Indexed keywords

BIOLOGICAL MARKER; CISAPRIDE; EBASTINE; MOXIFLOXACIN; NEUROLEPTIC AGENT; PENTOBARBITAL; POTASSIUM CHANNEL HERG; RANOLAZINE; THIORIDAZINE; VARDENAFIL;

ARRHYTHMOGENESIS; CARDIOTOXICITY; DRUG INDUCED DISEASE; DRUG OVERDOSE; DRUG SAFETY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE TACHYCARDIA; HUMAN; NONHUMAN; PHARMACOEPIDEMIOLOGY; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TORSADE DES POINTES;

ANIMALS; DRUG DESIGN; ELECTROCARDIOGRAPHY; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; TORSADES DE POINTES;

EID: 48149112290     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.215     Document Type: Review

References (21)

1. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM et al. (2004). Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110: 904-910.
2. Barbey JT, Lazzara R, Zipes DP (2002). Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther 7: 65-76.
3. Brass EP, Lewis RJ, Lipicky R, Murphy J, Hiatt WR (2006). Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk. Clin Pharmacol Ther 79: 165-172.
4. Darpo B (2001). Spectrum of drugs prolonging the QT interval and the incidence of torsades de pointes. Eur Heart J 3 (suppl. K): 70-80.
5. de Abajo FJ, Rodriguez LA (1999). Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol 47: 307-313.
6. Enger C, Cali C, Walker AM (2002). Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saf 11: 477-486.
7. FDA (2003). FDA review for Uroxatral (alfuzocin HCL tablets). Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3956B1_01_FDA-alfuzosin.pdf.
8. Hanrahan JP, Choo PW, Carlson W, Greineder D, Faich GA, Platt R (1995). Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol 5: 201-209.
9. Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K (2006). ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 54: 116-129.
10. ICH HARMONIZED TRIPARTITE GUIDELINE E14 (2005). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available at: http://www.ich.org/cache/compo/276-254- 1.html..
11. ICH HARMONIZED TRIPARTITE GUIDELINE S7B (2005). Safety pharmacology assessment of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Available at: http://www.ich.org/cache/ compo/276-254-1.html.
12. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S et al. (2007). Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 297: 1775-1783.
13. Omata T, Kasai C, Hashimoto M, Hombo T, Yamamoto K (2005). QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. J Pharmacol Sci 99: 531-541.
14. Paakkari I (2002). Cardiotoxicity of new antihistamines and cisapride. Toxicol Lett 127: 279-284.
15. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S et al. (1996). Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 131: 472-480.
16. Shah RR (2002a). Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol 16: 147-156.
17. Shah RR (2002b). Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol 16: 119-124.
18. Staffa JA, Jones JK, Gable CB, Verspeelt JP, Amery WK (1995). Risk of selected serious cardiac events among new users of antihistamines. Clin Ther 17: 1062-1077.
19. Strnadova C (2005). The assessment of QT/QTc prolongation in clinical trials: a regulatory perspective. Drug Information J 39: 407-433.
20. Tooley PJ, Vervaet P, Wager E (1999). Cardiac arrhythmias reported during treatment with cisapride. Pharmacoepidemiol Drug Saf 8: 57-58.
21. Walker AM, Szneke P, Weatherby LB, Dicker LW, Lanza LL, Loughlin JE et al. (1999). The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 107: 356-362.